These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10732322)

  • 21. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer.
    Hanstein B; Djahansouzi S; Dall P; Beckmann MW; Bender HG
    Eur J Endocrinol; 2004 Mar; 150(3):243-55. PubMed ID: 15012607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Selective estrogen receptor modulators (SERMs) in the practice].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions.
    Lonard DM; Smith CL
    Steroids; 2002 Jan; 67(1):15-24. PubMed ID: 11728517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor.
    Landry M; Di Paolo T
    Brain Res Mol Brain Res; 2003 Apr; 112(1-2):82-9. PubMed ID: 12670705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
    Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
    ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation.
    Nalbandian G; Paharkova-Vatchkova V; Mao A; Nale S; Kovats S
    J Immunol; 2005 Aug; 175(4):2666-75. PubMed ID: 16081843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
    Eisen SF; Brown HA
    Mol Pharmacol; 2002 Oct; 62(4):911-20. PubMed ID: 12237338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators.
    Moyle-Heyrman G; Schipma MJ; Dean M; Davis DA; Burdette JE
    J Ovarian Res; 2016 Feb; 9():5. PubMed ID: 26879975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals.
    Rando G; Horner D; Biserni A; Ramachandran B; Caruso D; Ciana P; Komm B; Maggi A
    Mol Endocrinol; 2010 Apr; 24(4):735-44. PubMed ID: 20197311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiestrogens--tamoxifen, SERMs and beyond.
    Dhingra K
    Invest New Drugs; 1999; 17(3):285-311. PubMed ID: 10665480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
    Reiter R; Oh AS; Wellstein A; Riegel AT
    Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular mechanisms involved in the protective actions of Selective Estrogen Receptor Modulators in brain cells.
    Baez-Jurado E; Rincón-Benavides MA; Hidalgo-Lanussa O; Guio-Vega G; Ashraf GM; Sahebkar A; Echeverria V; Garcia-Segura LM; Barreto GE
    Front Neuroendocrinol; 2019 Jan; 52():44-64. PubMed ID: 30223003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective estrogen receptor modulation: concept and consequences in cancer.
    Jordan VC
    Cancer Cell; 2004 Mar; 5(3):207-13. PubMed ID: 15050912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.
    Cerrato F; Fernández-Suárez ME; Alonso R; Alonso M; Vázquez C; Pastor O; Mata P; Lasunción MA; Gómez-Coronado D
    Br J Pharmacol; 2015 Mar; 172(5):1379-94. PubMed ID: 25395200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro.
    Nuttall ME; Fisher PW; Suva LJ; Gowen M
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S63-4. PubMed ID: 11056323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Estrogen receptor and selective estrogen receptor modulators (SERMs)].
    Shioi A; Nishizawa Y
    Nihon Rinsho; 1999 May; 57(5):1199-207. PubMed ID: 10361456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective oestrogen receptor modulators--current and future brain and behaviour applications.
    Halbreich U; Kahn LS
    Expert Opin Pharmacother; 2000 Dec; 1(7):1385-98. PubMed ID: 11249472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
    Muchmore DB
    Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.